Calidi Biotherapeutics Reports Q3 Financial Results, $6.9mln Raised

• Calidi Biotherapeutics presented new data at SITC annual meeting on CLD-401 • Data demonstrates platform can express genetic medicines at tumor site • Established new Scientific Advisory Board for CLD-401 development • Expanded RedTail platform capabilities with multiple payloads and targeting • Raised $6.9 million through underwritten public offering with new and existing investors.